Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

Publication | Closed Access

DOI

685

Citations

References

2008

Year

Bruno Chauffert, F. Mornex, F. Bonnetain, P. Rougier, C. Mariette, Olivier Bouché, J.-F. Bosset, Thomas Aparicio, Laurent Mineur, A. Azzedine,

Annals of Oncology

Intensive Induction ChemoradiotherapySurgical OncologyPancreatic CancerGastrointestinal OncologyMedicinePhase Iii TrialMaintenance GemcitabineCancer TreatmentOncologyRadiation OncologyCancer ResearchRadiologyHealth Sciences